Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2024-financial-results-and-business-update-302292332.html
SOURCE Rigel Pharmaceuticals, Inc.
Nachrichten zu Rigel Pharmaceuticals IncShs
Analysen zu Rigel Pharmaceuticals IncShs
Datum | Rating | Analyst | |
---|---|---|---|
01.03.2019 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
02.05.2018 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
15.12.2017 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
06.11.2017 | Rigel Pharmaceuticals Buy | H.C. Wainwright & Co. | |
09.03.2017 | Rigel Pharmaceuticals Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
01.03.2019 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
02.05.2018 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
15.12.2017 | Rigel Pharmaceuticals Overweight | Cantor Fitzgerald | |
06.11.2017 | Rigel Pharmaceuticals Buy | H.C. Wainwright & Co. | |
09.03.2017 | Rigel Pharmaceuticals Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
29.11.2012 | Rigel Pharmaceuticals neutral | UBS AG | |
24.07.2009 | Rigel Pharmaceuticals hold | Citigroup Corp. | |
28.10.2008 | Rigel Pharmaceuticals Downgrade | RBC Capital Markets | |
22.11.2007 | Rigel Pharmaceuticals neues Kursziel | Lehman Brothers Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
30.01.2009 | Rigel Pharmaceuticals underperform | RBC Capital Markets |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Rigel Pharmaceuticals IncShs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen